The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.